Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-07-08

Clinical Trial Update: Busonid® (Budesonide 200 mcg and 400 mcg) to Treat Asthma Not Controlled or Partially Controlled [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for Busonid (budesonide 200 mcg and 400 mcg) in asthma shows the study is suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Busonid (budesonide)

Snippet

Sponsor: Ache Laboratorios Farmaceuticos S.A. | Conditions: Asthma | Phase 3 | Status: SUSPENDED